Do PBMs, drug market brokers, have a stranglehold on prices that even Congress can’t break?

Indonesia Berita Berita

Do PBMs, drug market brokers, have a stranglehold on prices that even Congress can’t break?
Indonesia Berita Terbaru,Indonesia Berita utama

Drugmakers, pharmacies and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?

  • 📰 USATODAY
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 63%

The FTC under President Joe Biden has switched course, at least partly because of the arrival of Chair Lina Khan, a vigorous proponent of antitrust policy who launched an investigation of the PBMs last June.

And her reimbursements are “beyond low,” Seyfarth said. She laughed when asked whether contract terms with the PBMs were negotiable. “You aren’t negotiating anything,” she said. “It’s take it or leave it.” In October 2021, St. Clair’s treatment for a rare, non-smoking-related lung cancer was delayed three weeks after PBM giant Express Scripts insisted her prescription be filled by Accredo, the mail-order pharmacy it owns.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

USATODAY /  🏆 100. in İD
 

Indonesia Berita Terbaru, Indonesia Berita utama



Render Time: 2025-01-13 23:29:53